Novo Nordisk A/S files for regulatory approval of liraglutide 3 mg for the treatment of obesity

Novo Nordisk A/S files for regulatory approval of liraglutide 3 mg for the
treatment of obesity

Bagsvaerd, Denmark, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Bagsværd, Denmark, 20
December 2013 - Novo Nordisk today announced two separate regulatory
submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue,
as an adjunct to a reduced-calorie diet and increased physical activity for
chronic weight management in adults with obesity, or who are overweight with
comorbidities. The company filed a New Drug Application (NDA) with the U.S.
Food and Drug Administration (FDA) and a Marketing Authorisation Application
(MAA) with the European Medicines Agency (EMA).



Further information

Media:
Mike Rulis              +45 4442 3573   mike@novonordisk.com
Ken Inchausti (US)      +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen  +45 3079 4303   krop@novonordisk.com
Frank Daniel Mersebach  +45 3079 0604   fdni@novonordisk.com
Lars Borup Jacobsen     +45 3075 3479   lbpj@novonordisk.com
Daniel Bohsen           +45 3079 6376   dabo@novonordisk.com
Jannick Lindegaard (US) +1 609 235 8567 jlis@novonordisk.com

Company announcement No 78 / 2013 http://hugin.info/2013/R/1751528/590496.pdf

HUG#1751528
 
Press spacebar to pause and continue. Press esc to stop.